ES2904276T3 - Nanoestructuras de proteínas biológicamente activas sin vehículo - Google Patents

Nanoestructuras de proteínas biológicamente activas sin vehículo Download PDF

Info

Publication number
ES2904276T3
ES2904276T3 ES14789653T ES14789653T ES2904276T3 ES 2904276 T3 ES2904276 T3 ES 2904276T3 ES 14789653 T ES14789653 T ES 14789653T ES 14789653 T ES14789653 T ES 14789653T ES 2904276 T3 ES2904276 T3 ES 2904276T3
Authority
ES
Spain
Prior art keywords
protein
nanostructure
proteins
cells
nanogel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14789653T
Other languages
English (en)
Spanish (es)
Inventor
Li Tang
Darrell J Irvine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of ES2904276T3 publication Critical patent/ES2904276T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES14789653T 2013-09-27 2014-09-26 Nanoestructuras de proteínas biológicamente activas sin vehículo Active ES2904276T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361883503P 2013-09-27 2013-09-27
PCT/US2014/057789 WO2015048498A2 (en) 2013-09-27 2014-09-26 Carrier-free biologically-active protein nanostructures

Publications (1)

Publication Number Publication Date
ES2904276T3 true ES2904276T3 (es) 2022-04-04

Family

ID=51795741

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14789653T Active ES2904276T3 (es) 2013-09-27 2014-09-26 Nanoestructuras de proteínas biológicamente activas sin vehículo

Country Status (6)

Country Link
US (6) US9603944B2 (enExample)
EP (2) EP4043036A1 (enExample)
JP (3) JP7097667B2 (enExample)
CA (2) CA2925304C (enExample)
ES (1) ES2904276T3 (enExample)
WO (1) WO2015048498A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925304C (en) 2013-09-27 2023-04-18 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
AU2016305087B2 (en) * 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11123441B2 (en) * 2016-10-04 2021-09-21 The Trustees Of The University Of Pennsylvania Methods and compositions for drug delivery
CN111094330A (zh) 2017-07-03 2020-05-01 转矩医疗股份有限公司 编码免疫刺激融合分子的多核苷酸及其用途
CA3075027A1 (en) * 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Reversible linkers and use thereof
KR20210032924A (ko) * 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
EP3849569A4 (en) 2018-09-10 2022-06-08 Torque Therapeutics, Inc. ANTIGEN-SPECIFIC T LYMPHOCYTES AND METHODS OF MAKING AND USING THEM
BR112021019471A2 (pt) * 2019-03-29 2022-04-26 Torque Therapeutics Inc Composições imunoterapêuticas e uso das mesmas
FR3099052B1 (fr) * 2019-07-23 2022-03-25 Univ Franche Comte Structures particulaires à base de nanoparticules d’or, leurs procédés de préparation et leurs utilisations dans le traitement des tumeurs solides
EP3795172A1 (en) 2019-09-20 2021-03-24 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Polymer or polycondensate based on peptide, linker and optionally other monomers and method for preparing the same
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN112891556B (zh) * 2021-02-01 2023-03-03 浙江大学医学院附属第一医院 一种单抗类药物口服纳米凝胶及其制备方法
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN115746044A (zh) * 2022-09-27 2023-03-07 大连理工大学 一类含有链中柔性链段和脲键的硅烷偶联剂及其制备方法及其制备方法
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4525589A (en) 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
JPH03244601A (ja) 1990-02-22 1991-10-31 Masuko Suzuki マンナンと癌細胞分化誘導体の複合体、その製法及び抗癌剤
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5464629A (en) 1993-11-16 1995-11-07 Georgetown University Method of forming hydrogel particles having a controlled size using liposomes
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
IN190388B (enExample) 1997-10-01 2003-07-26 Biomira Usa Inc
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6319715B1 (en) 2000-04-21 2001-11-20 Cornell Research Foundation, Inc. Method of enhancing the delivery of nucleic acids using silica nanoparticles
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
EP1385479A4 (en) 2001-03-26 2006-12-06 Alza Corp LIPOSOMIC COMPOSITION FOR IMPROVED INTRA-CELLULAR RELEASE OF A THERAPEUTIC AGENT
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
WO2004032970A2 (en) 2002-10-10 2004-04-22 Samir Mitragotri Carriers attached to blood cells
US8192485B2 (en) * 2002-11-13 2012-06-05 The United States of America, as represented by the Department of Veterens Affairs Reversible hydrogel systems and methods therefor
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7223544B2 (en) 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
AU2005326322B2 (en) 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004054536A1 (de) 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
US20070148246A1 (en) 2005-08-11 2007-06-28 Dan Luo Nucleic Acid-Based Matrixes
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US20080267876A1 (en) 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
JP2007131568A (ja) 2005-11-09 2007-05-31 Nippon Seiyaku Kogyo Kk 免疫賦活剤及びこれを含有する免疫賦活性飲食物
SG172617A1 (en) 2005-12-12 2011-07-28 Ac Immune Sa Therapeutic vaccine
CN101309705A (zh) 2006-01-13 2008-11-19 独立行政法人理化学研究所 用于免疫疾病的预防或治疗剂以及方法
JP2009528292A (ja) 2006-02-27 2009-08-06 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ 生物学的障壁を越える増強された放出特性を有する分子の輸送のための組成物および方法
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2008057163A2 (en) * 2006-10-09 2008-05-15 Carnegie Mellon University Preparation of functional gel particles with a dual crosslink network
CN101909581B (zh) 2007-11-14 2012-11-14 加利福尼亚大学董事会 固醇修饰的两亲脂质
JP2009149526A (ja) 2007-12-18 2009-07-09 Tokyo Medical & Dental Univ サイトカイン−ナノゲル複合体を含む皮下注射又は筋肉内注射徐放製剤
WO2009134866A2 (en) 2008-04-29 2009-11-05 The Brigham And Women's Hospital, Inc. Cell membrane engineering
EP3936122A1 (en) 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
JP2012519733A (ja) 2009-03-09 2012-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 長期間の効果を有するタンパク質の送達のための単一タンパク質ナノカプセル
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
US20100324124A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
MX337393B (es) 2009-11-18 2016-03-02 Nektar Therapeutics Forma salina de un conjugado de polímero-farmaco con multiples brazos.
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
WO2011115684A2 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US9289505B2 (en) 2010-08-17 2016-03-22 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
US20130203675A1 (en) * 2010-09-16 2013-08-08 Joseph M. DeSimone Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US20140081012A1 (en) 2011-02-15 2014-03-20 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
EP2696887A4 (en) 2011-04-15 2015-01-07 Univ California POLYMER REDOX REACTION NANOCAPSULES FOR PROTEIN RELEASE
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
JP2013173689A (ja) 2012-02-24 2013-09-05 Univ Of Tsukuba 高分子化ニトロキシドラジカル化合物と非ステロイド性抗炎症薬の複合体
US20130337471A1 (en) 2012-06-14 2013-12-19 Emory University Cell identification with nanoparticles, compositions and methods related thereto
US9149535B2 (en) * 2012-06-28 2015-10-06 University Of South Carolina Polymers and the preparation of nanogel drug cocktails
FR3004106B1 (fr) 2013-04-05 2016-08-05 Oreal Composition contenant des particules composites filtrant les radiations uv de taille moyenne superieure a 0,1μm et des particules d'aerogel de silice hydrophobes
CA2953287A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
CA2925304C (en) 2013-09-27 2023-04-18 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
AU2016305087B2 (en) * 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018143976A1 (en) 2017-02-01 2018-08-09 Hewlett-Packard Development Company, L.P. Output tension zones

Also Published As

Publication number Publication date
US10357544B2 (en) 2019-07-23
US11529392B2 (en) 2022-12-20
CA3191031A1 (en) 2015-04-02
CA2925304A1 (en) 2015-04-02
WO2015048498A3 (en) 2015-07-23
JP7097667B2 (ja) 2022-07-08
US10588942B2 (en) 2020-03-17
US20200016238A1 (en) 2020-01-16
US20190083576A1 (en) 2019-03-21
EP3049114A2 (en) 2016-08-03
CA2925304C (en) 2023-04-18
US20150110740A1 (en) 2015-04-23
US20200360482A1 (en) 2020-11-19
WO2015048498A2 (en) 2015-04-02
WO2015048498A9 (en) 2016-01-28
JP2023103260A (ja) 2023-07-26
US20170196938A1 (en) 2017-07-13
US10226510B2 (en) 2019-03-12
EP4043036A1 (en) 2022-08-17
EP3049114B1 (en) 2021-11-10
US20230277626A1 (en) 2023-09-07
JP2020158537A (ja) 2020-10-01
JP7272664B2 (ja) 2023-05-12
JP2016533344A (ja) 2016-10-27
US9603944B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
US11529392B2 (en) Carrier-free biologically-active protein nanostructures
JP6887685B2 (ja) ナノ粒子の細胞表面共役
US20230381112A1 (en) Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
JP2020515629A (ja) 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
US10350298B2 (en) Immunomodulatory protein constructs with a helical polymeric backbone
ES2867398T3 (es) Nanosistemas para el transporte controlado de moléculas activas con fines diagnósticos, pronósticos y terapéuticos
Park et al. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells
JP5692887B1 (ja) ポリマーミセル医薬組成物
CA3074826A1 (en) Therapeutic protein compositions and methods of making and using the same
US9694085B2 (en) Targeted therapeutic nanoparticles
US20240042054A1 (en) Hydrogel compositions comprising gasdermin d and an escrt inhibitor and methods of use thereof
HK40079405A (en) Carrier-free biologically-active protein nanostructures
US20260091097A1 (en) Combination treatment regimes for treating cancer
채세열 Development of therapeutic protein carrier using porous silica nanomaterials
CN121015860A (zh) 一种疫苗及其制备方法和应用
Class et al. Patent application title: TARGETED THERAPEUTIC NANOPARTICLES Inventors: Roy R. Yeoman (Burke, VA, US) Richard A. Winchurch (Lutherville, MD, US) Assignees: NANODERM SCIENCES, INC.